U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPART MENTOF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 3

a collection of information diffess it displays a valid ONB control number.				
10/596,738				
06/22/2006				
VOORSPOELS, J.				
1615				
TIP-0048USPCT				

#### **U.S. PATENT DOCUMENTS**

		U.S. Patent Document  Kind Code <sup>2</sup> Number (if known)			Data of B. Itilianian	Daniel Calinera Linea
Examiner Initials	Cite No. <sup>1</sup>			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		5,993, 858		Port Systems, L.L.C.	11-30-1999	
		6,008,228		Hoffman-La Roche Inc.	12-28-1999	
		6,248,775	B1	G.D. Searle & Co.	06-19-2001	
		2003/004434	A1	Gao, P.	03-06-2003	
		6,054,136		Farah el al.	04-25-2000	
		6,312,704		Farah et al.	11-06-001	
		6,274,727		Maul et al.	08-14-2001	
		2004/0013697		Berndl et al.	01-22-2004	

### FOREIGN PATENT DOCUMENTS

		Foreign	Patent Documer	nt	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. <sup>1</sup>	Office <sup>3</sup>	Number <sup>4</sup> Kir	ndCode <sup>5</sup>	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T <sup>6</sup>
		EP	0435450	B1	ICI Americas Inc.	10-12-1994		
		EP	0715618	B1	G.D. Searle & Co.	12-16-1998		
		EP	1170003	B1	Hovid SDN BHD	04-05-2006		
		JP	2001- 151699		Nippon Kayaku Co. LTD (English abstract included & claim translation)	06-05-2001		
		wo	95/07596	A1	Abbott Laboratories	03-23-1995		
		wo	95/08983	A1	Gatte-Fosse S.A	04-06-1995	(US 6312704 and US 6054136 family members provided)	
		wo	96/39142	A1	F. Hoffman-La Roche AG	12-12-1996		
		wo	98/22106	A1	Abbott Laboratories	05-28-1998		
		wo	98/22094	A2	Merck Patent GMBH	05-28-1998		
		wo	99/06043	A1	Pharmacia & Upjohn Company	02-11-1999		

Exa	aminer	Date	
Sig	gnature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 3

a concentration and and a real control number:				
Application Number	10/596,738			
Filing Date	06/22/2006			
First Named Inventor	VOORSPOELS, J.			
Group Art Unit	1615			
Examiner Name				
Attorney Docket Number	TIP-0048USPCT			

U.S. PATENT DOCUMENTS								
		U.S. Patent Document			Date of Publication	Pages Columns Lines		
Examiner Initials	Cite No. <sup>1</sup>		nd Code <sup>2</sup> f known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear		
	FOREIGN PATENT DOCUMENTS							

#### Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or Examiner Cite passages or relevant mm-dd-yyyy $\mathsf{T}^6$ Applicant of Cited Document figures appear Initials KindCode<sup>5</sup> Office<sup>3</sup> Number<sup>4</sup> No.1 WO 99/06044 Α1 Pharmacia & Upjohn Company 02-11-1999 WO 99/67417 Α1 The Secretary, Department of 12-29-1999 Health and Human Services, USA 00/33862 WO Α1 Pharmasolutions, Inc. 06-15-2000 WO 01/34119 05-17-2001 A2 Abbott Laboratories WO 01/91727 A2 BASF Aktiengesellschaft 12-06-2001 WO 02/07712 Α2 Pharmacia & UpJohn Company; 01-31-2002 Sugen, Inc. WO 02/36110 АЗ Boehringer Ingelheim 05-10-2002 Pharmaceuticals, Inc. WO 03/049746 06-19-2003 **A3** Tibotec Pharmaceuticals, Ltd. WO 03/106461 Tibotec Pharmaceuticals, Ltd. 12-24-2003 A2 WO 98/22094 Merck Patent GMBH 05-28-1998 US 6274727 family member provided WO 01/91727 BASF Aktiengesellschaft 05/29/2001 US 2004/0013697 family member provided

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Under the Paperwork Reduction Act of 1995, no persons are required to respond to	a collection of information unless it displays a	valid OMB control number.
form 1449A/PTO	Application Number	10/596,738
	Filing Date	06/22/2006
ORMATION DISCLOSURE	First Named Inventor	VOORSPOELS, J.
TEMENT BY APPLICANT	Group Art Unit	1615
	Examiner Name	
(use as many sheets as necessary) Sheet 3 of 3	Attorney Docket Number	TIP-0048USPCT

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	$T^2$
Initials*	No. <sup>1</sup>	publisher, city and/or country where published	
		CHARMAN, W.N., "Lipids, Lipophilic Drugs, and Oral Drug Delivery-Some Emerging Concepts.", <u>Journal</u>	
		of Pharmaceutical Sciences, August 2000, Vol. 89, No. 8, pages 967-978.	
		CONSTANTINIDES, P.P., "Lipid Microemulsions For Improving Drug Dissolution And Oral Absorption:	
		Physical and Biopharmaceutical Aspects.", Pharmaceutical Research, 1995, Vol. 12, No. 11, pages 1561-	
		1572, Plenum Publishing Corporation.	
		GHOSH et al., "Potent HIV Protease Inhibitors Incorporating High-Affinity P2-Ligands and (R)-	
		(hydroxyethylamino)sulfonamide Isotere.", <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , 1998, Vol. 8, pages 687-690.	
		HUMBERSTONE et al., "Lipid-based Vehicles For The Oral Delivery Of Poorly Water Soluble Drugs.",	
		Advanced Drug Delivery Reviews, 1997, Vol. 25, pages 103-128.	
		POUTON, C. W., "Formulation Of Self-Emulsifying Drug Delivery Systems.", Advanced Drug Delivery	
		<u>Reviews</u> , 1997, Vol. 25, pages 47-58.	
		SWENSON et al., "Means to Enhance Penetration: (2) Intestinal Permeability Enhancement For Proteins,	
		Peptides and Other Polar Drugs: Mechanisms and Potential Toxicity.", <u>Advanced Drug Delivery Reviews</u> ,	
		1992, Vol. 8, pages 39-92, Elsevier Science Publishers B.V.	
l	I		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.